$2975 | SAVE $525 | Single User
$5950 | SAVE $1,050 | Site License
$8925 | SAVE $1,575 | Enterprise License

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018
[Report Updated: 20-11-2018]

Published by Global Markets Direct: 20 Nov 2018 | 227560 | In Stock
Related Topics: Bladder Cancer , Breast Cancer , Cancer , Colon Cancer , Colorectal Cancer , Hepatitis , Hodgkin Lymphoma , Leukemia , Lung Cancer , Lymphoma , Melanoma , Ovarian Cancer , Protein , Renal Cell Carcinoma

Introduction

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018

Summary

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 5, 1, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colon Cancer, Endometrial Cancer, Gastric Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Malignant Mesothelioma, Metastatic Breast Cancer, Metastatic Melanoma, Myelodysplastic Syndrome, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Squamous Non-Small Cell Lung Cancer.

The latest report Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2018, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)

- The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects

- The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development

    Aurigene Discovery Technologies Ltd

    BeiGene Ltd

    Bristol-Myers Squibb Co

    Eli Lilly and Co

    Elpiscience Biopharmaceuticals Co Ltd

    F. Hoffmann-La Roche Ltd

    GigaGen Inc

    Incyte Corp

    Interprotein Corp

    Jounce Therapeutics Inc

    Novartis AG

    Symphogen A/S

    TESARO Inc

    Trellis Bioscience Inc

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles

    BGBA-425 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    BMS-986258 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CA-170 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    CA-327 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    ES-001 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    INCAGN-2390 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    LY-3321367 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    MGB-453 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies 3 to Inhibit TIM3 for Solid Tumor - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibodies to Inhibit TIM-3 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Monoclonal Antibody to Inhibit CD366 for Melanoma - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    RO-7121661 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit TIM-3 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Sym-023 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TRL-6061 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    TSR-022 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products

    Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones

    Featured News & Press Releases

    Oct 01, 2018: TESARO announces data presentation on its melanoma drug candidate TSR-022 at the SITC 2018 Annual Meeting

    Jul 10, 2018: Selexis provides update on antibody candidate Sym023

    Apr 11, 2018: Agenus Presents preclinical data on INCAGN02390 at the American Association for Cancer Research (AACR) 2018 Annual Meeting

    Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

    Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit

    Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017

    Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress

    May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting

    Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170’s Phase 1 Trial at the SITC 2016 Conference

    Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

    Aug 08, 2016: Cancer Treatment Centers of America at Western Regional Medical Center is the first site in the world for new investigational anti-cancer treatment

    Jun 04, 2016: TESARO Provides Update on TSR-022 at ASCO Investor Briefing

    Jun 01, 2016: Curis Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints

    Apr 25, 2016: Tesaro Announces Submission Of Investigational New Drug Application For ANTI-TIM-3 Antibody TSR-022 To The US FDA

    Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CA-170 and PD-L1/TIM-3 Antagonist at AACR Annual Meeting

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

227560 | GMDHC1787TDB

Number of Pages

64

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Global Hepatitis Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Hepatitis C: Update Bulletin [February 2016]
IntroductionGain new KOL insights on the latest events that have the potential to shape the hepatiti...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Hepatitis C: KOL Insight
IntroductionThe Hepatitis C (HCV) market will be driven by meeting the needs of under-served patient...
01 Sep 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Physician Views: The hepatitis C pricing war - what impact on prescribers?
Scope In a surprise move, AbbVie agreed last month to provide its newly approved hepatitis C drug Vi...
29 Jan 2015 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Payer Insights: Hepatitis C
IntroductionThe race is on for the company that can competitively price treatment regimens, share da...
26 Sep 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Physician Views: Sovaldi revolutionises hepatitis C in the US, but what about uptake in the EU5?
Scope Uptake and usage of Gilead Sciences' Sovaldi (sofosbuvir) in the US market has been closely tr...
08 Jul 2014 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Physician Views – As hepatitis revolution gains pace, what are physician expectations for EASL 2014?
Scope With this year's meeting of the International Liver Congress (EASL) just over a week away (Apr...
01 Apr 2014 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Hepatitis C: Game changing regimens to revolutionise treatment landscape - Consensus Outlook
IntroductionThe worldwide hepatitis C (HCV) market is forecast to grow from .7 billion in 2012 to ...
01 Dec 2013 by FirstWord Pharma USD $4,246 (normally
USD $4,995)
More Info
SAVE 15% today! Physician Views: Entering the post-interferon era – will Gilead Sciences dominate hepatitis C?
Scope Consensus forecasts indicate that Gilead Sciences will dominate the market for all oral, inter...
01 Nov 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info
SAVE 15% today! Physician Views: What opportunity for Gilead Sciences' hepatitis C therapy sofosbuvir before interferon-sparing regiments reach the market?
ScopeOne of the key features of the hepatitis C treatment landscape over the past year to 18 months ...
01 Oct 2013 by FirstWord Pharma USD $591 (normally
USD $695)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...